Skip to main content
Acta Crystallographica Section F: Structural Biology and Crystallization Communications logoLink to Acta Crystallographica Section F: Structural Biology and Crystallization Communications
. 2011 May 25;67(Pt 6):682–684. doi: 10.1107/S1744309111011377

Crystallization and preliminary X-ray analysis of argininosuccinate lyase from Streptococcus mutans

Yan-Li Cao a,b, Gui-Lan Li b, Kai-Tuo Wang b, Hong-Yin Zhang a,*, Lan-Fen Li b,*
PMCID: PMC3107142  PMID: 21636911

Crystals of argininosuccinate lyase from S. mutans were obtained and X-ray data were collected to 2.5 Å resolution in space group R3.

Keywords: argininosuccinate lyase, Streptococcus mutans

Abstract

Argininosuccinate lyase (ASL) is an important enzyme in arginine synthesis and the urea cycle, which are highly conserved from bacteria to eukaryotes. The gene encoding Streptococcus mutans ASL (smASL) was amplified and cloned into expression vector pET28a. The recombinant smASL protein was expressed in a soluble form in Escherichia coli strain BL21 (DE3) and purified to homogeneity by two-step column chromatography. Crystals suitable for X-ray analysis were obtained and X-ray diffraction data were collected to a resolution of 2.5 Å. The crystals belonged to space group R3, with unit-cell parameters a = b = 254.5, c = 78.3 Å.

1. Introduction

Argininosuccinate lyase (argininosuccinase; ASL; EC 4.3.2.1) reversibly cleaves argininosuccinate to yield arginine and fumarate. The reaction provides arginine as a versatile substrate for the synthesis of urea, polyamines, creatine phosphate and nitric oxide. The enzyme plays a critical role not only in arginine synthesis and the urea cycle, but also in maintenance of the cellular nitrogen balance (Brosnan & Brosnan, 2007; Mori & Gotoh, 2004). ASL is classified into a superfamily of homotetrameric enzymes that catalyze similar β-­elimination reactions with cleavage of a C—N or C—O bond and subsequently releases fumarate as the elimination production (Toth & Yeates, 2000; Weaver & Banaszak, 1996; Fujii et al., 2003; Bhaumik et al., 2004). Recent studies on ASLs from different species have elucidated highly conserved regions that probably comprise the catalytic sites, such as Ser108, Arg109, Thr155, His156, Ser277 and Lys283 in Escherichia coli ASL, and are also observed in other ASLs (Sampaleanu et al., 2001, 2002; Vallée et al., 1999; Abu-Abed et al., 1997; Bhaumik et al., 2004; Fig. 1). An ASL structure including intact catalytic sites was first observed for E. coli ASL in the presence of phosphate ions (PDB entry 1tj7; Bhaumik et al., 2004), since the active site, which is mainly composed of loop regions, is most often flexible. Although the structure of Thermus thermophilus ASL complexed with l-arginine has been deposited (PDB entry 2e9f; M. Goto, unpublished work), precise descriptions of the β-elimination mechanism of ASLs based on reliable structural data are still lacking and the relationship between the structure and the function of ASLs remains obscure.

Figure 1.

Figure 1

Multiple sequence alignment of argininosuccinate lyase homologues using the program ClustalX (Thompson et al., 1997). ASLs from the following organisms were selected: Streptococcus mutans (S. mutan), Escherichia coli (E. coli), Thermus thermophilus (T. th), Homo sapiens (Human), duck δ-crystallin (Duck) and goose δ-crystallin (Goose). The sequence identities of the homologues to smASL are given after the names. The conserved residues that probably constitute the active site are highlighted in grey.

Streptococcus mutans is the principal acidogenic component of dental plaque, which causes tooth demineralization and dental caries (Mosci et al., 1990). smASL (gi:24376709; Gene ID 1029354) encoded by the gene smu.335 consists of 460 amino-acid residues with a predicted molecular mass of 51.5 kDa. Based on sequence alignment, smASL shows about 42–49% sequence identity to other known ASL structures (Fig. 1). In this work, we report the preparation, crystallization and preliminary X-ray analysis of smASL. The ultimate structural determination of smASL should help us to promote further studies of ASLs.

2. Materials and methods

2.1. Cloning and protein expression

The smASL gene was amplified from S. mutans strain UA159 genomic DNA by polymerase chain reaction and cloned into the BamHI and XhoI restriction-enzyme sites of pET28a vector using conventional cloning techniques. The primers used were the forward primer 5′-CGCGGATCCATGACAACAAAAAATCACAAATT-3′ and the reverse primer 5′-CCGCTCGAGTTAAAGTGCTTTTTTAGCCTCT-3′. The recombinant plasmid con­taining an N-terminal His6 tag was confirmed by nucleotide sequencing and transformed into the host E. coli BL21 (DE3) (Novagen). The transformed cells were cultured in Luria–Bertani (LB) medium containing 50 µg ml−1 kanamycin at 310 K. At an OD600 of 0.6, expression of smASL was induced with isopropyl β-­d-1-thiogalactopyranoside at a final con­centration of 0.5 mM. The cells were incubated for a further 5 h at 303 K before being harvested by centrifugation at 6600g for 10 min, resuspended in lysis buffer consisting of 20 mM Tris–HCl pH 7.5 and 500 mM NaCl and lysed by sonication.

2.2. Protein purification

The disrupted cells were centrifuged at 34 700g for 50 min at 277 K. The supernatant was filtered and loaded onto a 5 ml HiTrap Ni2+-chelating affinity column (GE Healthcare, USA) equilibrated with lysis buffer. smASL protein was eluted with a linear gradient of 50–500 mM imidazole in lysis buffer. Further purification was carried out by size-exclusion chromatography using a 120 ml HiLoad Superdex 200 column (GE Healthcare, USA) equilibrated with 20 mM Tris–HCl pH 7.5 and 150 mM NaCl. SDS–PAGE was used to examine the purity of the protein at each step. The purified protein was concentrated to around 10 mg ml−1 (yielding approximately 15 mg per litre of culture) using ultrafiltration (Millipore Amicon Ultra-15, 10 kDa cutoff). The protein concentration was measured using the Bio-Rad Protein Assay Kit (Bio-Rad, USA).

2.3. Crystallization and X-ray diffraction data collection

Initial crystallization trials of purified protein with the His-tag fusion were performed at 289 K by the sitting-drop vapour-diffusion method using an XtalQuest 482 crystallization plate (XtalQuest Inc., Beijing, People’s Republic of China). A total of three commercial screening kits, Crystal Screen, Crystal Screen 2 and Index Screen (Hampton Research, California, USA), were used in initial crystallization trials. 1 µl protein solution was mixed with 1 µl reservoir solution and the droplet was equilibrated against 100 µl reservoir solution.

X-ray diffraction data were collected at a wavelength of 0.9795 Å using a MAR CCD 225 detector on the BL17U beamline at Shanghai Synchrotron Radiation facility (SSRF), Shanghai, People’s Republic of China. The smASL protein crystal was soaked in 2 M 1,6-hexane­diol in 100% paraffin oil for ∼5 s before being flash-cooled and kept at 100 K in a cold nitrogen stream during data collection. A total of 100 frames were collected with 1° oscillation per frame. The exposure time was 1 s per image. The data were processed using the program XDS (Kabsch, 2010).

3. Results and discussion

The smASL protein was expressed in E. coli BL21 (DE3) with a typical yield of about 15 mg pure protein per litre of cell culture. After two-step chromatographic purification, homogenous samples suitable for crystallization trials were obtained. The size-exclusion chromatography results indicated that the protein exists mainly in a tetrameric form in solution (Fig. 2). The molecular weight shown on SDS–PAGE is consistent with the theoretical molecular mass of 51.5 kDa plus ∼4.0 kDa for the fusion part (MGSSHHHHHHSSG­LVPRGSHMASMTGGQQMGRGS).

Figure 2.

Figure 2

Chromatogram of smASL on a Superdex 200 column (GE Healthcare, USA). The UV280nm absorption curves of standard proteins (Bio-Rad Laboratories, USA) and smASL are shown as red dashed and blue solid lines, respectively.

Crystals suitable for data collection were obtained in a condition consisting of 0.056 M sodium dihydrogen phosphate, 1.344 M di­potassium hydrogen phosphate pH 8.2 (Fig. 3 a). Typical crystal dimensions were approximately 0.20 × 0.20 × 0.40 mm. The crystallized protein was confirmed by an SDS–PAGE analysis of dissolved crystals (Fig. 3 b). The crystal diffracted to a resolution of 2.5 Å and belonged to space group R3. Assuming the presence of four molecules in the asymmetric unit, the Matthews coefficient (V M) was calculated to be 2.4 Å3 Da−1 (Matthews, 1968), with an estimated solvent content of 48.2%. The data-collection statistics are summarized in Table 1. The structure of smASL will be solved by the molecular-replacement method using the structure of E. coli ASL (PDB entry 1tj7; Bhaumik et al., 2004), which has 46% sequence identity, as a search model.

Figure 3.

Figure 3

(a) Crystals of S. mutans argininosuccinate lyase grown in 0.056 M sodium dihydrogen phosphate, 1.344 M dipotassium hydrogen phosphate pH 8.2 using the sitting-drop vapour-diffusion method. (b) 15% SDS–PAGE gel with Coomassie Brilliant Blue staining. Lane 1, molecular-weight protein markers (kDa); lane 2, dissolved smASL crystal sample.

Table 1. Data-collection statistics.

Values in parentheses are for the highest resolution shell.

Wavelength (Å) 0.9791
Space group R3
Unit-cell parameters (Å, °) a = b = 254.5, c = 78.3, α = 90, β = 90, γ = 120
Resolution range (Å) 50–2.5 (2.6–2.5)
Completeness (%) 95.2 (86.6)
No. of observed reflections 198922
No. of unique reflections 62263
Average I/σ(I) 13.8 (3.4)
Rmerge (%) 5.9 (33.8)
No. of molecules per asymmetric unit 4
Solvent content (%) 48.2
VM3 Da−1) 2.4

R merge = Inline graphic Inline graphic.

Acknowledgments

This work was supported by a grant from the National Natural Science Foundation of China (30530190). Peking University’s 985 and 211 grants are also gratefully acknowledged. We are grateful to Drs Yuhe Liang and Jie Nan for comments and for proofreading the manuscript. We thank the beamline staff at SSRF for their help during data collection.

References

  1. Abu-Abed, M., Turner, M. A., Vallée, F., Simpson, A., Slingsby, C. & Howell, P. L. (1997). Biochemistry, 36, 14012–14022. [DOI] [PubMed]
  2. Bhaumik, P., Koski, M. K., Bergmann, U. & Wierenga, R. K. (2004). Acta Cryst. D60, 1964–1970. [DOI] [PubMed]
  3. Brosnan, M. E. & Brosnan, J. T. (2007). J. Nutr. 137, 1656S–1661S. [DOI] [PubMed]
  4. Fujii, T., Sakai, H., Kawata, Y. & Hata, Y. (2003). J. Mol. Biol. 328, 635–654. [DOI] [PubMed]
  5. Kabsch, W. (2010). Acta Cryst. D66, 125–132. [DOI] [PMC free article] [PubMed]
  6. Matthews, B. W. (1968). J. Mol. Biol. 33, 491–497. [DOI] [PubMed]
  7. Mori, M. & Gotoh, T. (2004). J. Nutr. 134, 2820S–2825S. [DOI] [PubMed]
  8. Mosci, F., Perito, S., Bassa, S., Capuano, A. & Marconi, P. F. (1990). Minerva Stomatol. 39, 413–429. [PubMed]
  9. Sampaleanu, L. M., Vallée, F., Slingsby, C. & Howell, P. L. (2001). Biochemistry, 40, 2732–2742. [DOI] [PubMed]
  10. Sampaleanu, L. M., Yu, B. & Howell, P. L. (2002). J. Biol. Chem. 277, 4166–4175. [DOI] [PubMed]
  11. Thompson, J. D., Gibson, T. J., Plewniak, F., Jeanmougin, F. & Higgins, D. G. (1997). Nucleic Acids Res. 25, 4876–4882. [DOI] [PMC free article] [PubMed]
  12. Toth, E. A. & Yeates, T. O. (2000). Structure, 8, 163–174. [DOI] [PubMed]
  13. Vallée, F., Turner, M. A., Lindley, P. L. & Howell, P. L. (1999). Biochemistry, 38, 2425–2434. [DOI] [PubMed]
  14. Weaver, T. & Banaszak, L. (1996). Biochemistry, 35, 13955–13965. [DOI] [PubMed]

Articles from Acta Crystallographica Section F: Structural Biology and Crystallization Communications are provided here courtesy of International Union of Crystallography

RESOURCES